Rocket Pharma director gets RSUs and options

ROCKET PHARMACEUTICALS, INC. director Mikael Dolsten reported routine equity compensation awards rather than open-market trades.

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. director Mikael Dolsten reported routine equity compensation awards rather than open-market trades. He received 22,862 restricted stock units that convert into common stock on a one-for-one basis and 64,860 stock options with an exercise price of $3.35 per share.

The RSUs and options both vest in full on June 18, 2027, with the options expiring on June 18, 2036. After the RSU grant, Dolsten directly holds 67,082 shares of common stock. The filing reflects compensation-related acquisitions, not purchases or sales in the market.

Insider Trade Summary

Grant/Award: 87,722 shares

Grant/Award 2 txns

Insider Dolsten Mikael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	64,860	$0.00	$0.00
Grant/Award	Common Stock	22,862	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 64,860 contracts (Direct); Common Stock — 67,082 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
2. F2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

Key Figures

RSU grant size: 22,862 RSUs Option grant size: 64,860 options Option exercise price: $3.35 per share +3 more

6 metrics

RSU grant size 22,862 RSUs Restricted stock units granted on June 18, 2026

Option grant size 64,860 options Stock options granted on June 18, 2026

Option exercise price $3.35 per share Exercise price for 64,860 stock options

Common shares held after grant 67,082 shares Total Rocket Pharmaceuticals common stock directly held after RSU grant

Vesting date June 18, 2027 Both RSUs and options vest in full on this date

Option expiration June 18, 2036 Expiration date of the granted stock options

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), vest in full, fully vested and exercisable, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price and expiration date."

vest in full financial

"The RSUs will vest in full on June 18, 2027."

fully vested and exercisable financial

"All of which will become fully vested and exercisable on June 18, 2027."

exercise price financial

"Conversion or exercise price of 3.3500 per share for the options."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Rocket Pharmaceuticals (RCKT) director Mikael Dolsten receive?

Mikael Dolsten received 22,862 restricted stock units and 64,860 stock options in Rocket Pharmaceuticals. The RSUs convert one-for-one into common stock, while the options give him the right to buy common shares at a fixed exercise price.

When do Mikael Dolsten’s Rocket Pharmaceuticals RSUs and options vest?

Both the RSUs and stock options vest in full on June 18, 2027. This means Dolsten must remain eligible through that date to receive the shares or exercise the options, aligning his compensation with Rocket Pharmaceuticals’ longer-term performance.

What is the exercise price and expiration date of Dolsten’s Rocket Pharmaceuticals options?

Dolsten’s stock options carry a $3.35 exercise price and expire on June 18, 2036. He can choose to buy Rocket Pharmaceuticals common shares at $3.35 any time after vesting and before the expiration date, subject to plan terms.

How many Rocket Pharmaceuticals shares does Mikael Dolsten hold after these grants?

Following the RSU grant, Dolsten directly holds 67,082 shares of Rocket Pharmaceuticals common stock. This total reflects his post-transaction position as reported, giving investors context on his direct ownership stake after the compensation awards.

Are Mikael Dolsten’s recent Rocket Pharmaceuticals transactions open-market buys or sells?

These transactions are compensation-related equity awards, not open-market buys or sells. The Form 4 shows grants of RSUs and stock options at no cash cost per share, rather than discretionary purchases or sales through the public market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 07:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dolsten Mikael

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NEW JERSEY 08512

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/18/2026		A(2)		22,862	A	$0(2)	67,082	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.35	06/18/2026		A		64,860		(2)	06/18/2036	Common Stock	64,860	$0	64,860	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.

2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

	/s/ Martin Wilson, as attorney-in-fact for Mikael Dolsten	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)